<DOC>
	<DOCNO>NCT01532804</DOCNO>
	<brief_summary>This phase 2 trial aim evaluate continue use bevacizumab raltitrexed oxaliplatin combination versus FOLFOX6 plus bevacizumab patient metastatic colorectal cancer whose disease progress irinotecan-based chemotherapy .</brief_summary>
	<brief_title>2nd-line Treatment Metastatic Colorectal Cancer</brief_title>
	<detailed_description>Eligible patient randomly allocate receive either bevacizumab raltitrexed oxaliplatin combination bevacizumab FOLFOX 6 combination . Random allocation schedule perform use minimization technique follow stratification factor : - Center - Number metastatic site : 1 versus &gt; 1 - Bevacizumab-based first-line therapy : Yes versus No</detailed_description>
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<mesh_term>Oxaliplatin</mesh_term>
	<mesh_term>Raltitrexed</mesh_term>
	<criteria>Histologically proven colorectal cancer Resected asymptomatic primary tumor Metastatic colorectal cancer eligible curative surgery No major surgery within four week start study treatment At least one target lesion unidimensionally measurable crosssectional imaging accord RECIST criterion ( v1.1 ) Disease progression failure irinotecanbased chemotherapy Bone metastases allow least one measurable metastatic site CT scan abdomen , chest pelvis within 3 week start study treatment WHO PS â‰¤ 2 Platelet count &gt; = 100,000 mm3 Hemoglobin &gt; 10g/dl Bilirubin &lt; 1.5 ULN , AST/ALT &lt; 5 ULN Serum creatinine &lt; 1.5 ULN , creatinine clearance &gt; 60 ml/min ( Cockcroft ) A time period 4 week respect end previous treatment study enrollment Negative pregnancy test woman childbearing potential Male female use effective contraceptive method Absence know symptomatic brain metastasis Life expectancy &gt; 3 month Informed consent sign prior study specific procedure Prior raltitrexedbased chemotherapy Prior oxaliplatinbased chemotherapy ( except adjuvant treatment complete 6 month ) Uncontrolled arterial hypertension define systolic pressure &gt; 150 mm Hg diastolic pressure &gt; 100 mm Hg Malignant hypertension hypertensive encephalopathy Myocardial infarction , pulmonary embolism , severe vascular disease within 6 month prior study entry Hemorrhagic diathesis significant pathology coagulation Peripheral neuropathy grade &gt; 2 ( NCICTC v4.0 ) Hemoptysis &lt; 1 month Venous access device ( PAC ) minor surgery biopsy within last 7 day Symptomatic brain metastasis carcinomatous meningitis History presence cancer within past 5 year ( except curatively treat nonmelanoma skin cancer situ cervical cancer ) Severe bacterial fungal infection ( Grade &gt; 2 NCICTCAE v.4.0 ) Known suspect sensitivity one study drug Pregnant breastfeed woman Previous enrollment investigational drug study within last 4 week Psychological , social , geographical disorder condition would preclude study compliance ( treatment administration study followup )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2015</verification_date>
	<keyword>Unresectable metastasis</keyword>
</DOC>